Guggenheim analyst Subbu Nambi noted that Grail (GRAL) announced a partnership yesterday with Quest Diagnostics (DGX) to offer Galleri, Grail’s multi-cancer early detection, or MCED, test. The firm, which views this distribution partnership as a positive for Grail as it simplifies the ordering process and leverages Quest’s network and infrastructure to make Galleri more accessible to U.S. patients, keeps a Neutral rating on Grail shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRAL: